A diagnostic device (1) for detecting a first member of a reporter-analyte pair. The diagnostic device comprises an inlet for receiving a liquid, biological sample and a porous membrane element (10) comprising a detection portion. The detection portion is in liquid communication with the inlet and a second member of the reporter-analyte pair is immobilised on the detection portion. One of the first or second member of the reporter-analyte pair comprises a biological antigen and the other of the first or second member of the reporter-analyte pair comprises an antibody specific for the biological antigen. The biological antigen comprises a spike protein, or a fragment thereof, of COVID-19. The device is for independent detection of the spike protein, or the fragment thereof, or of an antibody specific for the spike protein, or the fragment thereof, in the biological sample.

Disclosed herein are recombinant viruses and/or insect cells suitable for detecting the infection of a pathogen in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the pathogen or not, so that proper course of treatment may be assigned to the subject. Also disclosed herein is a vaccine for the prophylaxis and/or treatment of infection caused by said pathogen.

The present disclosure provides engineered SARS-CoV-2 spike ectodomain polypeptides and cells for producing such a polypeptide, as well as compositions and methods thereof.

The present invention provides microfluidic porous substrate-based devices for multiplexed biosensing. The devices are suitable for detecting viruses and bacteria, such as by way of detecting pathogenic genes and antibodies. The devices support reverse transcriptase loop-mediated isothermal amplification for rapid results within minutes. The devices also support vertical-lateral-vertical direction flow assays, such as in the form of a multi-layered adhesive bandage.

The present disclosure is directed to a relief system for the effective detection, prevention, and treatment of COVID-19, including (1) serological diagnostic assays for the detection of viral infection and epidemiological surveillance, (2) high-precision, site-directed peptide immunogen constructs for the prevention of infection by SARS-CoV-2, (3) receptor-based antiviral therapies for the treatment of the disease in infected patients, and (4) designer protein vaccine containing S1-RBD-sFc. The disclosed relief system utilizes amino acid sequences from SARS-CoV-2 proteins as well as human receptors for the design and manufacture of optimal SARS-CoV-2 antigenic peptides, peptide immunogen constructs, CHO-derived protein immunogen constructs, long-acting CHO-derived ACE2 proteins, and formulations thereof, as diagnostics, vaccines, and antiviral therapies for the detection, prevention, and treatment of COVID-19.

A biosensor comprising an electrode and inverted molecular pendulums (iMPs) is described. Each IMP includes a linker bound to the electrode, and an analyte receptor and a redox reporter both bound to the linker. The redox reporter is reactive at positive potential when the linker presents a net negative charge and reactive at negative potential when the linker presents a net positive charge. Upon application of an electric field, the biosensor is characterized by an iMPs unbound state, where no analyte is bound to the receptor, at which the iMPs are displaced towards the electrode and electron transfer from the iMPs towards the electrode occurs at an unbound electron transfer rate, and an iMPs bound state, where the analyte is bound to the receptor, at which the iMPs are displaced towards the electrode and electron transfer from the iMPs towards the electrode occurs at a bound electron transfer rate.

Provided herein is a rapid lateral flow device for detection of a target analyte in a liquid biological sample comprising a membrane strip, the membrane strip including: a matrix; a conjugate pad having at least one reporter vitrified into the matrix; one or more test sites including a covalently or electrostatically bound capture agent vitrified into or onto the matrix; and, optionally, a control line including one or more capture agents vitrified into or onto the matrix. Also provided are methods of rapid detection of a target analyte in a liquid biological sample.

Disclosed herein are methods and composition useful for the detection of HPV in a subject sample.

The present disclosure relates to novel epitope-based compositions, including vaccines, against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and diseases caused by SARS-CoV-2, including the highly contagious coronavirus disease 2019. The disclosure relates to immunogenic polypeptides (including concatemeric polypeptides, hybrid Ii-key constructs, and chimeric or fusion polypeptides as disclosed herein) and the uses thereof, particularly in vaccine compositions. The disclosure also relates to nucleic acids, vectors, and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an agretope predicted to be a ligand of HLA class I and/or HLA class II MHC molecules, as well as an epitope that is predicted to be recognized by T-cells in the context of MHC class I and/or class II molecules. The compositions are particularly suited to produce vaccines, particularly for vaccinating against SARS-CoV-2 infection and related diseases caused by SARS-CoV-2, including COVID-19.

Calibration and/or quality control reagents are disclosed for use in serology immunoassays for antibodies to a microorganism. In the reagents, antibodies specific to an antigen of the microorganism are complexed with anti-human Ig antibody to form a complex. Kits and microfluidics devices containing the reagents are also disclosed, along with methods of producing and using the reagents.